{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-004724","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.961264+00:00","generated_at":"2026-06-05T23:10:49.988576+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monopar receives Australian ethics clearance to start Phase 1 trial of radiopharmaceutical MNPR-101-Zr","bullets":["HREC clearance in Australia to commence Phase 1 dosimetry trial of MNPR-101-Zr for advanced cancers.","Trial will enroll ~12 patients using PET imaging to assess tumor uptake, biodistribution, and safety.","MNPR-101-Zr is a zirconium-89 labeled version of Monopar's uPAR-targeting antibody; preclinical data showed selective uptake.","If Phase 1 encouraging, Monopar plans to evaluate therapeutic version bound to actinium-225 (Ac-225).","This is Monopar's first human clinical trial using its uPAR targeting agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-004724","json":"https://secwatch.observer/filing/0001437749-24-004724.json","markdown":"https://secwatch.observer/filing/0001437749-24-004724.md","text":"https://secwatch.observer/filing/0001437749-24-004724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924004724/0001437749-24-004724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924004724/mnpr20240216_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T23:10:49.988576+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}